New Wave Biotech Partners with Temasek’s Nurasa to Digitise Bioprocess Scaling in Asia

UK-based AI simulation specialist New Wave Biotech has entered a commercial partnership with Nurasa, the sustainable food and nutrition company owned by Temasek. The collaboration aims to accelerate the commercialisation of alternative protein and food-tech innovations by merging New Wave’s digital predictive capabilities with Nurasa’s physical infrastructure.

The partnership addresses critical bottlenecks in the biomanufacturing sector, specifically the high cost and time constraints associated with scaling products from the laboratory to industrial viability.

Virtualising the Scale-Up Process

Under the agreement, Nurasa’s ecosystem of startups and corporate partners will gain access to New Wave Biotech’s Bioprocess Foresight platform. This software solution allows companies to virtually test thousands of downstream processing scenarios, significantly reducing the reliance on slow and expensive physical experimentation.

Key Technical Capabilities:

Virtual Optimisation: The software has proven capable of reducing physical experiments by up to 90% and halving unit costs.
Integrated Analysis: The platform automates Techno-Economic Analysis (TEA) and Life-Cycle Assessment (LCA), providing visibility on cost, yield, and environmental trade-offs long before capital is committed to physical infrastructure.

Strategic Hub in Singapore

While New Wave Biotech provides the digital layer, Nurasa contributes the physical and regulatory ecosystem necessary for market entry in Asia. Based in Singapore, Nurasa offers food-grade pilot facilities, application development expertise, and go-to-market partnerships.

Samson Lee, Strategic Partnerships Manager at Nurasa, highlighted Singapore's role as a regional launchpad: “Singapore is strengthening its position as a hub for scalable, sustainable nutrition and biomanufacturing innovation. Integrating New Wave Biotech’s bioprocess simulation and TEA/LCA contextualisation capabilities into our platform of offerings strengthens our ability to guide both startups and corporates toward commercially viable production, not just technical validation.”

Zoe Yu Tung Law, Co-Founder and CEO of New Wave Biotech, emphasised the need for data-driven clarity during the development phase:

“Scaling biomanufacturing depends on understanding not just how a process behaves, but what that means for cost, yield and sustainability. Our platform predicts technical outcomes and contextualises them through TEA and LCA, giving teams clear, data-driven insight at every stage of development. By partnering with Nurasa, we can support both startups and established companies in progressing from lab to commercially viable manufacturing with far greater clarity and lower risk.”